NCT06057103View on ClinicalTrials.gov

A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

December 5, 2023

Study Completion Date

April 26, 2024

Conditions
Drug Interaction
Interventions
DRUG

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

DRUG

Oseltamivir

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

DRUG

ZX-7101A and Oseltamivir

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

DRUG

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

DRUG

Oseltamivir

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

DRUG

ZX-7101A and Oseltamivir

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

DRUG

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Nanjing Zenshine Pharmaceuticals

INDUSTRY